Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...

Gepotidacin inhibits DNA replication via two ... could claim 10 million deaths a year by 2050. "The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in ...

The US Food and Drug Administration (FDA) recently approved Blujepa (gepotidacin), a ground-breaking oral antibiotic for treating uncomplicated urinary tract infections (UTIs). This is the first new ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.